Summary: A team of scientists at Tongji University just announced a breakthrough in regenerating human lungs using stem cells, improving lung function in patients. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

A team of researchers from Tongji University in China announced what they say is a breakthrough in treating lung diseases by regenerating tissue using stem cell transplantation.

In a pilot clinical trial, the treatment proved effective at repairing the lung tissue of two patients suffering from lung diseases, who showed improvements in both symptoms and on CT scans, say the researchers. Zuo Wei is a Tongji University professor who led the research team and says.

The AHA names evolocumab — a new PCSK9 inhibitor — as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8, 2018. However, this novel cholesterol-lowering drug carries a big price tag.

Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8. However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances in heart disease and stroke research, published on February 8. Evolocumab belongs to a class of cholesterol-lowering drugs called PCSK9 inhibitors and is injectable drug marketed by Amgen under the brand name Repatha. The two-year FOURIER study reported that evolocumab reduced high cholesterol levels and had few adverse effects.

The FOURIER study, published in the New England Journal of Medicine, found that evolocumab can significantly reduce heart attacks and strokes among high-risk patients. The study included more than 27,000 patients who were randomized into taking evolocumab or a placebo, and showed that the new drug has a clear benefit over statins in reducing LDL, the bad cholesterol in patients. FOURIER showed that the new medication cut the risk of having a heart attack, stroke or other cardiovascular events by 20% when added to intensive statin therapy. The study was paid for by Amgen and reported that evolocumab lowered LDL by about 60%, to a median of 30 mg/dL.

In a first for medical science, scientists in the UK have successfully created functioning human kidney tissue that produces urine.

Summary: In a first for medical science, researchers in the UK have successfully created functioning human kidney tissue that produces urine. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

In a first for medical science, researchers have successfully created human kidney tissue within a living organism which can produce urine.

The study led by professor Sue Kimber and professor Adrian Woolf from the University of Manchester in the UK marks a significant milestone in the development of kidney disease treatments. The scientists published their results on February 8 in the journal Stem Cell Reports.

Researchers just reported promising rapamycin clinical trial results in the first of its kind test of the drug’s safety and anti-aging effects on healthy Senior adults. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

A rapamycin clinical trial using healthy adults recently completed and reported the drug to be safe over the short-term when used for anti-aging purposes.

This clinical trial of rapamycin was one of the first testing the compound’s safety as an anti-aging drug in healthy Seniors. The clinical trial consisted of 25 healthy older adults 70–95 years between the ages of 70 to 95. The study participants took either a placebo or 1mg rapamycin daily for eight weeks. The main finding of the study was that the drug was safe, without significant side effects. The researchers published their results on February 3 in the journal Experimental Gerontology and concluded.